Diagnosis and management of multiple myeloma (Q43817786)

27 November 2017

Diagnosis and management of multiple myeloma. (English)

1 reference

27 November 2017

UK myeloma forum. British Committee for Standards in Haematology

series ordinal

1

1 reference

PubMed ID

11736932

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

British Journal of Haematology

27 November 2017

1 reference

27 November 2017

115

1 reference

27 November 2017

3

1 reference

27 November 2017

522-540

1 reference

A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma.

27 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

VAD-based regimens as primary treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

The role of chemotherapy in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

European best practice guidelines for the management of anaemia in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Interaction of the protein C/protein S anticoagulant system, the endothelium and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Oral dosage of melphalan and response to treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Intensive treatment for multiple myeloma: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Cytokine therapy in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Hemibody irradiation. An effective second-line therapy in drug-resistance multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Risk of disease progression in asymptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.03206.X

10.1046/J.1365-2141.2001.03206.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference

PubMed ID

11736932